Table 2 —
Patient and tumor characteristics.
| Characteristic | Cohort Patients (%) | Validation Grp 1 (Australia) | Validation Grp 2 (MD Anderson) | Validation Grp 3 (Ascende-RT) |
|---|---|---|---|---|
| No. of Patients | 8,746 | 366 | 221 | 160 |
| Baseline PSA Level, ng/mL, median | 6.2 | 5.5 | 5.1 | 10.0 |
| <4 | 1184 (13.5) | 76 (20.8) | 56 (25.4) | 7 (4.4) |
| ≥4–<10 | 6154 (70.4) | 279 (76.2) | 157 (71.0) | 68 (42.5) |
| ≥10–<20 | 1202 (13.7) | 11 (3.0) | 8 (3.6) | 60 (37.5) |
| ≥20–<30 | 119 (1.4) | 0 (0.0) | 0 (0.0) | 17 (10.6) |
| ≥30 | 87 (1.0) | 0 (0.0) | 0 (0.0) | 8 (5.0) |
| Not reported | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Gleason Score | ||||
| ≤6 | 4739 (54.2) | 314 (85.8) | 10 (4.5) | 10 (6.3) |
| 7 | 3379 (38.6) | 52 (14.2) | 211 (95.5) | 81 (50.6) |
| 8 | 362 (4.1) | 0 (0.0) | 0 (0.0) | 37 (23.1) |
| 9 or 10 | 232 (2.7) | 0 (0.0) | 0 (0.0) | 32 (20.0) |
| Not reported | 34 (0.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| T Category | ||||
| T1a-T2a | 7376 (84.3) | 325 (88.8) | 217 (98.2) | 67 (41.9) |
| T2b-T2c | 1093 (12.5) | 41 (11.2) | 4 (1.8) | 49 (30.6) |
| T3a-T3b | 61 (0.7) | 0 (0.0) | 0 (0.0) | 44 (27.5) |
| Not reported | 216 (2.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Age, years, median | 66.0 | 61.0 | 64.9 | 67 |
| <50 | 156 (1.8) | 5 (1.4) | 9 (4.1) | 0 (0.0) |
| ≥50–<60 | 1803 (20.6) | 136 (37.1) | 48 (21.7) | 21 (13.1) |
| ≥60–<70 | 4162 (47.6) | 176 (48.1) | 114 (51.6) | 64 (40.0) |
| ≥70 | 2624 (30.0) | 49 (13.4) | 50 (22.6) | 75 (46.9) |
| Not reported | 1 (0.0) | 0 (0.0) | 0 (0) | 0 (0.0) |
| No. of PSA measurements | ||||
| <10 | 2443 (27.9) | 0 (0.0) | 42 (19.0) | 4 (2.5) |
| ≥10–<20 | 4777 (54.6) | 254 (69.4) | 172 (77.8) | 105 (65.6) |
| ≥20 | 1526 (17.5) | 112 (30.6) | 7 (3.2) | 51 (31.9) |
| PSA follow-up, years, median, maximum | 7.8 (19.7) | 12.1 (18.9) | 6.0 (12.2) | 9.7 (15.5) |